ZEVASKYN Patient Count Jumps to 12, Payer Coverage Tops 95%
ABEO sits 35% above its 52-week low of $4.
Summary
Abeona's ZEVASKYN launch is accelerating: 12 patients treated, up from five at the Q2 report, with seven centers covering ~40% of the addressable population and payer coverage exceeding 95%. The company also licensed AAV204 ophthalmology capsids to Beacon and acquired PSMA-SIR-T, which enters human trials next year. This follows the Q2 revenue beat of $11.4M (up 31% sequentially) and the FDA approval of Ultragenyx's UX111, a program Abeona originally developed. The expanded patient count and near-universal payer coverage suggest commercial traction is building faster than initially reported. Watch for Q3 revenue to confirm the launch trajectory.
At the time of this announcement, ABEO was trading at $5.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $308.8M. The 52-week trading range was $4.00 to $7.65. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.